Search results
Ganchimeg Ulziisaikhan
Research Area(s) / Expertise:
Job title: Cardiologist
Author
CPET and Exercise Prescription for Cardiac Rehabilitation
Author(s):
Kaoutar Kabbadj
,
Nora Taiek
,
Wiame El Hjouji
,
et al
Added:
1 year ago
Review Article
Tariq Ahmad
Research Area(s) / Expertise:
Author
Expertise
Guidelines & StatementsHeart FailureHeart Failure Services, Prevention and Digital HealthVascular Disease and SurgeryElectrophysiology & ArrhythmiaDigital HealthPrevention & Chronic ConditionsInterventionDigital Health and Artificial IntelligencePeripheral Artery Disease - GeneralAnticoagulationCardiovascular Kidney MetabolicChronic Heart Failure ManagementImaging & DiagnosticsCardiomyopathies and Cardiac Amyloidosis
Amin Yehya
Research Area(s) / Expertise:
Author
Expertise
Guidelines & StatementsHeart FailureHeart Failure Services, Prevention and Digital HealthVascular Disease and SurgeryElectrophysiology & ArrhythmiaDigital HealthPrevention & Chronic ConditionsInterventionDigital Health and Artificial IntelligencePeripheral Artery Disease - GeneralAnticoagulationCardiovascular Kidney MetabolicChronic Heart Failure ManagementImaging & DiagnosticsCardiomyopathies and Cardiac Amyloidosis
Vijay U Rao
Research Area(s) / Expertise:
Job title: Director Heart Failure, Cardio-oncology and Co-Director Anticoagulation at Franciscan St Francis Health
Author
Author(s):
Milind Y Desai
Added:
1 year ago
AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.The REMS program investigated the safety and efficacy of…
View more
Paul Kalra
Research Area(s) / Expertise:
Author
Expertise
Guidelines & StatementsHeart FailureHeart Failure Services, Prevention and Digital HealthVascular Disease and SurgeryElectrophysiology & ArrhythmiaDigital HealthPrevention & Chronic ConditionsInterventionDigital Health and Artificial IntelligencePeripheral Artery Disease - GeneralAnticoagulationCardiovascular Kidney MetabolicChronic Heart Failure ManagementImaging & DiagnosticsCardiomyopathies and Cardiac Amyloidosis
Leway Chen
Research Area(s) / Expertise:
Author
Expertise
Guidelines & StatementsHeart FailureHeart Failure Services, Prevention and Digital HealthVascular Disease and SurgeryElectrophysiology & ArrhythmiaDigital HealthPrevention & Chronic ConditionsInterventionDigital Health and Artificial IntelligencePeripheral Artery Disease - GeneralAnticoagulationCardiovascular Kidney MetabolicChronic Heart Failure ManagementImaging & DiagnosticsCardiomyopathies and Cardiac Amyloidosis
Added:
9 months ago
Source:
Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide…
View more
Author(s):
Biykem Bozkurt, Pardeep Jhund, Muthiah Vaduganathan
Start date:
Sep 11, 2024
Join us for an unparalleled educational journey dedicated to tackling the complexities of managing HFpEF and HFmrEF patients. This CME-accredited live roundtable is chaired by Dr Biykem Bozkurt (Baylor College of Medicine, US) and features insights from renowned experts Prof Pardeep Jhund (University of Glasgow, UK) and Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical…
View more